title: Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence.
abstract: This post hoc analysis compared the safety of atomoxetine treatment of ADHD in adults with or without comorbid alcohol abuse/dependence. Study completion rates in patients receiving atomoxetine were comparable between heavy drinkers (60.9%) and patients with no alcohol-use disorder (71.0%) but lower in nonheavy drinkers (35.7%); however, there was no significant difference in discontinuation rates due to adverse events or lack of efficacy among these groups. Alcohol-use disorder patients, especially heavy drinkers, generally experienced the greatest frequency of treatment-emergent adverse events in both the atomoxetine and placebo groups. Vital signs and measures of hepatic function were not significantly different among the 3 drinking status groups taking atomoxetine.
authors.affiliation: Department of Psychiatry and Child and Adolescent Psychiatry, New York University Langone School of Medicine, 530 First Avenue, #7D, New York NY 10016, USA. lenard.adler@med.nyu.edu
authors.forename: Lenard
authors.initials: L
authors.lastname: Adler
authors.forename: Timothy
authors.initials: T
authors.lastname: Wilens
authors.forename: Shuyu
authors.initials: S
authors.lastname: Zhang
authors.forename: Todd
authors.initials: T
authors.lastname: Durell
authors.forename: Daniel
authors.initials: D
authors.lastname: Walker
authors.forename: Leslie
authors.initials: L
authors.lastname: Schuh
authors.forename: Ling
authors.initials: L
authors.lastname: Jin
authors.forename: Peter
authors.initials: P
authors.lastname: Feldman
authors.forename: Paula
authors.initials: P
authors.lastname: Trzepacz
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects*; D000328:Adult; D000437:Alcoholism / Q000150:complications / Q000188:drug therapy*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy*; D017831:Diagnosis, Dual (Psychiatry); D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D011437:Propylamines / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D055986:Vital Signs
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride